Clenbuterol
As of the edition of 20 October 2026, Clenbuterol is a small molecule: marketed; acts on ADRB2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Small molecule
- Brand name
- Clembroxol
- Approvals on record
- 4 in 4 regions
- Holder of the most recent approval
- Sopharma Ad; 4 holders in all
- Registered trials
- 12, 2 stopped early
- Disease areas
- Nervous system; Inherited and neonatal; Nutrition and metabolism; Bones, joints and muscles; Heart and blood vessels; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| ADRB2 | Beta-2 adrenergic receptor | P07550 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 1 | 0 | 0 |
| Phase 1 | 2 | 0 | 1 | 1 |
| Phase 2 | 7 | 5 | 1 | 1 |
| All trials | 12 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| CuraSen Therapeutics | Lead sponsor of trials | 2021 to now |